Tony, There is no mention of usenet in the article. I am called an Internet poster which is how SI is accessed. As far as the nuisance part is concerned, I do run into occasional whiners, but the postive replies on the boards or via E-Mail far outstrips the moaners and groaners.
Speaking of moaning and groaning, it might be more appropriate to talk about the AMLN portion of the article:
"A deal with Johnson & Johnson would be noteworthy for its effects on Amylin
Pharmaceuticals (AMLN:Nasdaq), which has a big deal with J&J on its
compound, pramlintide. Two weeks ago, Amylin fell 43% after mixed results
in two studies of its drug in Type I and Type II patients. The company's
trials did not meet statistical significance in Type II patients, and
investors are concerned that the effect seen in the Type I patients wasn't
dramatic. If Ligand signs a deal with J&J, investors would take the move as
a sign that J&J wasn't thrilled with its Amylin alliance and might back off
from it. However, the future of diabetes treatment, as in cancer and AIDS,
may be in cocktail therapy, meaning that pramlintide may be useful in
combination with other drugs." |
